Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 10, 2009, Pages 4761-4768

  Lu, Peirong ^a,b   Li, Longbiao ^a   Liu, Gaoqin ^a   Zhang, Xueguang ^a   Mukaida, Naofumi ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MESSENGER RNA; VASCULOTROPIN; DIFFERENTIATION ANTIGEN; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; NOS2 PROTEIN, MOUSE; SODIUM HYDROXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CAUSTIC BURN; CELL INFILTRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; GENE EXPRESSION; GENE LOCATION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CHEMICAL BURN; CHEMICALLY INDUCED DISORDER; CORNEA; DISEASE MODEL; DRUG EFFECT; EYE BURN; FLUORESCENT ANTIBODY TECHNIQUE; MACROPHAGE; METABOLISM; MOUSE MUTANT; NEUTROPHIL; PHYSIOLOGY;

ANIMALS; ANTIGENS, DIFFERENTIATION; BURNS, CHEMICAL; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; EYE BURNS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MACROPHAGES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEUTROPHILS; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM HYDROXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349562400     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2732     Document Type: Article

References (48)

1. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
2. Epstein RJ, Stulting RD, Hendricks RL, et al. Corneal neovascularization: pathogenesis and inhibition. Cornea. 1987;6: 250-257.
3. Klintworth GK, Burger PC. Neovascularization of the cornea: current concepts of its pathogenesis. Ophthalmol Clin. 1983;23:27-39.
4. Ambati BK, Joussen AM, Kuziel WA, et al. Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea. 2003;22: 465-467.
5. Ambati BK, Anand A, Joussen AW, et al. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci. 2003;44:590-593.
6. Lu P, Li L, Mukaida N, et al. Alkali-induced corneal neovascularization is independent of CXCR2-mediated neutrophil infiltration. Cornea. 2007;26:199-206.
7. Sakurai E, Anand A, Ambati BK, et al. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3578-3585.
8. Tsutsumi-Miyahara C, Sonoda KH, Egashira K, et al. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularization. Br J Ophthalmol. 2004;88: 1217-1222.
9. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;21:119-126.
10. Tsutsumi C, Sonoda KH, Egashira K, et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol. 2003;74:25-32.
11. Taub DD. Chemokine-leukocyte interactions: the voodoo that they do so well. Cytokine Growth Factor Rev. 1996;7:355-376.
12. Ishida Y, Kondo T, Kimura A, et al. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-κB activation and a reciprocal suppression of TGF-β signal pathway. J Immunol. 2006;176:5598-5606.
13. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323-340.
14. Matsushima K, Oppenheim JJ. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine. 1989;1:2-13.
15. Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27-55.
16. Lu P, Li L, Zhang X. Expression of proinflammatory cytokine, chemokine and its receptor in mouse cornea after alkali injury (in Chinese). Chin Ophthalmol Res. 2007;25:256-260.
17. Biswas PS, Banerjee K, Kim B, Rouse BT. Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis: possible role for IL-1 in herpetic stromal keratitis pathogenesis. J Immunol. 2004;172:3736-3744.
18. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea. 1998;17:403-409.
19. Stapleton WM, Chaurasia SS, Medeiros FW, Mohan RR, Sinha S, Wilson SE. Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea. Exp Eye Res. 2008;86: 753-757.
20. Dana MR, Yamada J, Streilein JW. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation. 1997;63:1501-1507.
21. Yamada J, Dana MR, Zhu SN, Alard P, Streilein JW. Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation. Arch Ophthalmol. 1998;116:1351-1357.
22. Yamada J, Zhu SN, Streilein JW, Dana MR. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci. 2000;41:4203-4208.
23. Lu P, Li L, Kuno K, et al. Protective roles of the fractalkine/ CX3CL1-CX3CR1 interactions in alkali-induced corneal neovascularization through enhanced antiangiogenic factor expression. J Immunol. 2008;108:4283-4291.
24. Fujioka N, Mukaida N, Harada A, et al. Preparation of specific antibodies against murine IL-1ra and the establishment of IL-1ra as an endogenous regulator of bacteria-induced fulminant hepatitis in mice. J Leukoc Biol. 1995;58:90-98.
25. Iizasa H, Yoneyama H, Mukaida N, et al. Exacerbation of granuloma formation in IL-1 receptor antagonist-deficient mice with impaired dendritic cell maturation associated with Th2 cytokine production. J Immunol. 2005;174:3273-3280.
26. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103:11405-11410.
27. Apte RS, Richter J, Herndon J, et al. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 2006;3:1371-1381.
28. Li J, Perrella MA, Tsai JC, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem. 1995;270:308-312.
29. Ben-Av P, Crofford LJ, Wilder RL, et al. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372:83-87.
30. Solà-Villa D, Camacho M, Solà R, et al. IL-1β induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells. Kidney Int. 2006;70:1935-1941.
31. Kondo T, Ohshima T. The dynamics of inflammatory cytokines in the healing process of mouse skin wound: a preliminary study for possible wound age determination. Int J Legal Med. 1996;108: 231-236.
32. Galkowska H, Olszewski WL, Wojewodzka U. Keratinocyte and dermal vascular endothelial cell capacities remain unimpaired in the margin of chronic venous ulcer. Arch Dermatol Res. 2005; 296:286-295.
33. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45:1117-1124.
34. Gao G, Li Y, Zhang D, et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001;489:270-276.
35. Gao G, Ma J. Tipping the balance for angiogenic disorders. Drug Discov Today. 2002;7:171-172.
36. Zhang SX, Ma JX. Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res. 2007;26:1-37.
37. Ando A, Yang A, Mori K, et al. Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol. 2002;191:116-124.
38. Abu EI-Asrar AM, Meersschaert A, Dralands L, et al. Inducible nitric oxide synthase and vascular endothelial growth factor are colocalized in the retinas of human subjects with diabetes. Eye. 2004;18: 306-313.
39. Colotta F, Sironi M, Borrè A, et al. Type II interleukin-1 receptor is not expressed in cultured endothelial cells and is not involved in endothelial cell activation. Blood. 1993;81:1347-1351.
40. Dewberry R, Holden H, Crossman D, et al. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2394-2400.
41. Gottsäter A, Forsblad J, Mätzsch T, et al. Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies. J Intern Med. 2002;251:61-68.
42. Bertini R, Sironi M, Martin-Padura I, et al. Inhibitory effect of recombinant intracellular interleukin 1 receptor antagonist on endothelial cell activation. Cytokine. 1992;4:44-47.
43. Józkowicz A, Dulak J. Effects of protoporphyrins on production of nitric oxide and expression of vascular endothelial growth factor in vascular smooth muscle cells and macrophages. Acta Biochim Pol. 2003;50:69-79.
44. Leibovich SJ, Chen JF, Pinhal-Enfield G, et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol. 2002;160:2231-2244.
45. Vila-del Sol V, Díaz-Muñoz MD, Fresno M. Requirement of tumor necrosis factor α and nuclear factor-βB in the induction by IFN-γ of inducible nitric oxide synthase in macrophages. J Leukoc Biol. 2007;81:272-283.
46. Geismann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71-82.
47. Janson RW, Hance KR, Arend WP. Production of IL-1 receptor antagonist by human in vitro-derived macrophages: effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor. J Immunol. 1991;147:4218-4223.
48. Rupp J, Kothe H, Mueller A, et al. Imbalanced secretion of IL-1β and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J. 2003;22:274-279.